Brief: Ceapro Says Its Therapeutic May Be Suitable For Fibrotic Lung Disease And Late Stage COVID-19 Patients

Ceapro

11/11/2021 13:37

Nov 11 (Reuters) - Ceapro Inc  CZO.V :
    * CEAPRO INC. PROVIDES UPDATE ON DEVELOPMENT OF AN INHALABLE
THERAPEUTIC USING YEAST BETA GLUCAN PROCESSED WITH PRESSURIZED
GAS EXPANDED TECHNOLOGY (PGX-YBG)
    * CEAPRO INC - PGX-YBG DEMONSTRATES ABILITY TO REPROGRAM
MACROPHAGES ON ITS OWN
    * CEAPRO INC - PGX-YBG MAY BE A SUITABLE THERAPEUTIC
SOLUTION FOR
PATIENTS WITH FIBROTIC LUNG DISEASE AND LATE STAGE COVID-19
PATIENTS

Source text for Eikon:  ID:nGNX7y02Qz 
Further company coverage:  CZO.V 

 ((Reuters.Briefs@thomsonreuters.com;))